- Home
- NVAX vs SABR Comparison
NVAX vs SABR Comparison
Compare NVAX & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- SABR
- Stock Information
- Founded
- NVAX 1987
- SABR 2006
- Country
- NVAX United States
- SABR United States
- Employees
- NVAX N/A
- SABR N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- SABR Computer Software: Programming Data Processing
- Sector
- NVAX Health Care
- SABR Technology
- Exchange
- NVAX Nasdaq
- SABR Nasdaq
- Market Cap
- NVAX 1.3B
- SABR 1.2B
- IPO Year
- NVAX 1995
- SABR 2014
- Fundamental
- Price
- NVAX $7.84
- SABR $1.79
- Analyst Decision
- NVAX Hold
- SABR Buy
- Analyst Count
- NVAX 6
- SABR 5
- Target Price
- NVAX $15.00
- SABR $4.12
- AVG Volume (30 Days)
- NVAX 8.6M
- SABR 12.1M
- Earning Date
- NVAX 08-06-2025
- SABR 08-07-2025
- Dividend Yield
- NVAX N/A
- SABR N/A
- EPS Growth
- NVAX N/A
- SABR N/A
- EPS
- NVAX 2.54
- SABR N/A
- Revenue
- NVAX $1,078,718,000.00
- SABR $3,010,157,000.00
- Revenue This Year
- NVAX $52.02
- SABR $2.06
- Revenue Next Year
- NVAX N/A
- SABR $4.53
- P/E Ratio
- NVAX $3.08
- SABR N/A
- Revenue Growth
- NVAX 9.22
- SABR 6.13
- 52 Week Low
- NVAX $5.01
- SABR $1.73
- 52 Week High
- NVAX $15.22
- SABR $4.63
- Technical
- Relative Strength Index (RSI)
- NVAX 48.26
- SABR 23.45
- Support Level
- NVAX $7.57
- SABR $1.74
- Resistance Level
- NVAX $10.64
- SABR $1.86
- Average True Range (ATR)
- NVAX 0.72
- SABR 0.13
- MACD
- NVAX -0.07
- SABR -0.04
- Stochastic Oscillator
- NVAX 29.47
- SABR 4.41
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company announced a planned sale of its growing hotel IT solutions division (9% of revenue) to TPG for $960 million in net proceeds, which is scheduled to close in late 2025. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.